文献速递免疫规划传染病防控与疫情报告

美国2021年18岁及以下儿童青少年免疫规划推荐

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-02-12

在FDA紧急使用授权后,ACIP先后对≥16岁人群的Pfizer-BioNTech COVID-19疫苗和≥18岁人群的Moderna COVID-19疫苗作出临时推荐,并将COVID-19疫苗推荐纳入该规划。

要点

  • ACIP批准2021年18岁及以下儿童青少年免疫规划
  • Pfizer-BioNTech COVID-19疫苗获≥16岁人群临时推荐
  • Moderna COVID-19疫苗获≥18岁人群临时推荐

核心结论

  • ACIP批准2021年儿童青少年免疫规划,并将COVID-19疫苗推荐纳入其中。

主要发现

  • ACIP对≥16岁人群的Pfizer-BioNTech COVID-19疫苗发出临时推荐。
  • ACIP对≥18岁人群的Moderna COVID-19疫苗发出临时推荐。

关键数值与推荐

  • 2021年推荐适用于18岁及以下儿童青少年。
  • Pfizer-BioNTech COVID-19疫苗临时推荐适用于≥16岁人群。
  • Moderna COVID-19疫苗临时推荐适用于≥18岁人群。

临床怎么用

  • 按2021年ACIP儿童青少年免疫规划实施接种,并关注COVID-19疫苗临时推荐的人群范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

At its October 2020 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the 2021 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger. After Emergency Use Authorization of Pfizer-BioNTech COVID-19 vaccine by the Food and Drug Administration (FDA), ACIP issued an interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years at its December 12, 2020, meeting (1). In addition, ACIP approved an amendment to include COVID-19 vaccine recommendations in the child and adolescent immunization schedule. After Emergency Use Authorization of Moderna COVID-19 vaccine by FDA, ACIP issued an interim recommendation for use of Moderna COVID-19 vaccine in persons aged ≥18 years at its December 19, 2020, emergency meeting (2).

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Wodi AP, Ault K, Hunter P, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33571172. doi:10.15585/mmwr.mm7006a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。